Clinical Observation Of Adjuvant Endocrine Therapy In Breast Cancer Which The Molecular Type Was ER (-) PR (+)

Objective: To investigate the prognostic value of ER(-)PR(+)breast cancer patients receiving_adjuvant endocrine therapy,to make clear the effect of adjuvant endocrine therapy on this type of breast cancer patients;To analyze the clinical and pathological features of breast cancer through pathological data of breast cancer patients.Methods: Reviewed the patients of breast Department in the second hospital of Shanxi Medical University from Juary 2006 to June 2016,collect clinical pathological data and select Breast cancer patients who received tamoxifen treatment and the molecular type was ER(-)PR(+)18 cases as observation group and type was ER(+)PR(+)20 cases ascontrol group,selecting breast cancer patients the molecular type was ER(-)PR(+)15 cases who did not receive tamoxifen treatment as blank control group.To make clear the effect of adjuvant endocrine therapy on ER(-)PR(+)breast cancer patients and analyze pathological features of ER(-)PR(+)breast cancer patients through analyzing and comparring the disease-free survival(DFS)of three groups of breast cancer patients.And univariate and multivariate prognostic analysis of ER(-)PR(+)groups of patients.Results: ER(-)PR(+)patients have a higher proportion of premenopausal,the median age of onset was 47 years,with large toumor,with axillary lymph node metastasis,and most patients with high risk of recurrence risk.After a mean follow-up of 50 months,the65.5% of DFS for 5 years in ER(-)PR(+)breast cancer patients who receive tamoxifen treatment group was significantly lower than 83.3% of that in ER(-)PR(+)breast cancer patients,but was significantly higher than 11.3% of that in ER(-)PR(+)breast cancer patients who did not receive tamoxifen treatment group.The results of comparison between groups showed that the prognosis of ER(-)PR(+)breast cancer patients receiving endocrine therapy group was worse than that of ER(+)PR(+)group,the difference was statistically significant(p=0.042).The 5 year DFS was significantly higher in ER(-)PR(+)breast cancer patients who receive tamoxifen treatment group than that who did not receive tamoxifen treatment group,the difference was statistically significant(p=0.048).Multivariate analysis showed that the menstrual status was an independent prognostic factor.Conclusion: ER(-)PR(+)breast cancer patients benefit from adjuvant endocrine therapy.The biological behavior of ER(-)PR(+)tumor tissue was relatively poor,with high risk of recurrence in most ER(-)PR(+)breast cancer patients.